Suven Pharmaceuticals Ltd reported a 40% YoY revenue growth in Q3 FY25, achieving adjusted EBITDA margins of 38.7% on a proforma basis with reported revenue of Rs 6.76bn for Suven+Cohance, while standalone revenue was Rs 3.07bn with margins of 44.9%.